💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Deferiprone

CHEMBL70927 Phase 4 승인됨 Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
139.2 g/mol
LogP
0.5
Phase
4

An oral iron chelator used to treat iron overload in thalassemia patients when other chelation therapies are inadequate or not tolerated. It binds excess iron and removes it primarily through the urine. A potentially serious side effect is agranulocytosis, a dangerous drop in white blood cells, which requires regular blood count monitoring.

분자량

139.1500 g/mol

LogP

0.50

TPSA

40.50 Ų

리핀스키 5의 법칙

통과

치료 영역

Cardiovascular Disease Osteoporosis Alzheimer's Disease Parkinson's Disease Stroke Hypertension

작용 기전

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1c(O)c(=O)ccn1C

                

                

                
                

                    
InChI

                    
InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C7H9NO2

                    

                    
                    

                        
HBD / HBA

                        
1 / 3

                    

                    
                    

                        
회전 가능 결합

                        
0

                    

                    
                    
                    

                        
무거운 원자

                        
10

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
An oral iron chelator used to treat iron overload in thalassemia patients when other chelation therapies are inadequate or not tolerated. It binds excess iron and removes it primarily through the urine. A potentially serious side effect is agranulocytosis, a dangerous drop in white blood cells, which requires regular blood count monitoring.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Deferiprone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL70927.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2972.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.